Selenium-binding protein 1 may decrease gastric cellular proliferation and migration

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1620-1629

  Zhang, Chenjing ^a   Xu, Wen ^a   Pan, Wensheng ^a,b   Wang, Nana ^c   Li, Guogang ^b   Fan, Xiaoyuan ^d   Xu, Xiang ^b   Shen, Shengrong ^b   Das, Undurti N ^e  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Department of Internal Medicine   (China)

^d Yinzhou People's Hospital   (China)

^e UND LIFE SCIENCES   (United States)

Author keywords

Cellular proliferation and migration; Gastric cancer; Selenium binding protein1

Indexed keywords

CISPLATIN; SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; SELENIUM-BINDING PROTEINS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875992483     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1850     Document Type: Article

References (23)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006. (Pubitemid 46630593)
2. Lee JH, Kim KM, Cheong JH and Noh SH: Current management and future strategies of gastric cancer. Yonsei Med J 53: 248-257, 2012.
3. Xia YJ, Ma YY, He XJ, Wang HJ, Ye ZY and Tao HQ: Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. Hum Pathol 42: 1620-1628, 2011.
4. Zhang J, Dong WG and Lin J: Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol 28: 481-487, 2011.
5. Zhang P, Zhang C, Wang X, et al: The expression of selenium-binding protein 1 is decreased in uterine leiomyoma. Diagn Pathol 5: 80, 2010.
6. Silvers AL, Lin L, Bass AJ, et al: Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 16: 2009-2021, 2010.
7. Zhang C, Wang YE, Zhang P, et al: Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Hum Pathol 41: 255-261, 2010.
8. Wu C, Luo Z, Chen X, et al: Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep 21: 1429-1437, 2009.
9. Pohl NM, Tong C, Fang W, Bi X, Li T and Yang W: Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One 4: e7774, 2009.
10. Li T, Yang W, Li M, et al: Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52: 1289-1299, 2008.
11. Chen G, Wang H, Miller CT, et al: Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202: 321-329, 2004. (Pubitemid 38325241)
12. Kim H, Kang HJ, You KT, et al: Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6: 3466-3476, 2006. (Pubitemid 43886162)
13. Pan S, Cheng L, White JT, et al: Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS 13: 345-354, 2009.
14. Huang C, Ding G, Gu C, et al: Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1alpha to promote hepatocellular carcinoma invasiveness. Clin Cancer Res 18: 3042-3053, 2012.
15. Jeong JY, Wang Y and Sytkowski AJ: Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun 379: 583-588, 2009.
16. Raucci R, Colonna G, Guerriero E, et al: Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta 1814: 513-522, 2011.
17. Porat A, Sagiv Y and Elazar Z: A 56-kDa selenium-binding protein participates in intra-Golgi protein transport. J Biol Chem 275: 14457-14465, 2000. (Pubitemid 30339732)
18. Rayman MP: Selenium and human health. Lancet 379: 1256-1268, 2012.
19. Scortegagna M, Martin RJ, Kladney RD, Neumann RG and Arbeit JM: Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res 69: 2638-2646, 2009.
20. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM and Chiu JF: Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4: 3276-3287, 2004. (Pubitemid 39372407)
21. Zhang J, Zhan N and Dong WG: Altered expression of selenium-binding protein 1 in gastric carcinoma and precursor lesions. Med Oncol 28: 951-957, 2011.
22. Blot WJ, Li JY, Taylor PR, et al: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483-1492, 1993. (Pubitemid 23269183)
23. Cho YM, Bae SH, Choi BK, et al: Differential expression of the liver proteome in senescence accelerated mice. Proteomics 3: 1883-1894, 2003.